Potent Phase 1 inflammation data drives BGE-102 into two POC trials; cardiovascular readout will show whether NLRP3 inhibition translates to clinical benefit

Updated 41d ago

BioAge Labs is a clinical-stage company developing a targeted inflammation drug for cardiovascular disease and diabetic eye disease that is not yet approved.

BGE-102, an oral NLRP3 inhibitor, produced 86% median hsCRP reductions and 90-98% IL-1 suppression in Phase 1 with no serious adverse events, establishing target engagement but not yet clinical efficacy. Whether that pharmacology translates to meaningful outcomes in cardiovascular risk and diabetic macular edema remains the central unresolved question. The obesity APJ portfolio is entirely pre-IND, making BGE-102 the sole near-term value driver, and the cardiovascular readout carries the full weight of the thesis.

Status

Intact

Conviction

Current Thesis Drivers

Phase 1: 86-98% IL-1/hsCRP suppression, no SAEs
QUELL-CV Phase 2 and QUELL-DME Phase 1b/2a initiated
$381M cash, ~$24M/qtr burn, runway to 2029
Clinical efficacy in CV or DME unproven — POC open

What could change the thesis?

QUELL-CV hsCRP readout YE 2026: hit validates NLRP3 thesis, miss deflates both programs
QUELL-DME mid-2027 POC: ocular efficacy signal opens indication, null ends DME expansion
APJ IND filing 2026: human-ready advances obesity optionality, failure narrows pipeline to BGE-102

Generated from public SEC filings and disclosures. For informational purposes only — not investment advice. Always conduct your own research before making investment decisions.

Thesis log

Tracked in real time as it happened — not reconstructed after the fact

Key value driver

The most decisive event ahead

Bull and bear case

Both sides of the thesis, argued

Pipeline

4 programs · 6 catalysts

Stress Test